Recent FDA action (through September 2009) related to cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, and beclomethasone 17,21-dipropionate
Complete response
Recommended for approval
Not recommended for approval
Orphan drug designation
Get the latest industry news, event updates, and more from Managed healthcare Executive.